Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q6SA08

UPID:
TSSK4_HUMAN

ALTERNATIVE NAMES:
Serine/threonine-protein kinase 22E

ALTERNATIVE UPACC:
Q6SA08; Q2TA60; Q6ZNM2

BACKGROUND:
The enzyme Testis-specific serine/threonine-protein kinase 4, also known as Serine/threonine-protein kinase 22E, is integral to the development of male germ cells and the functionality of mature sperm. It is believed to be involved in the Cre/Creb signaling pathway, with the ability to phosphorylate CREB1 on 'Ser-133', CREM on 'Ser-116', and ODF2 on 'Ser-95'. These actions suggest its critical role in modulating cellular signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Testis-specific serine/threonine-protein kinase 4 offers promising avenues for therapeutic intervention, especially in treating male infertility. Its key role in sperm development and function underscores its potential as a therapeutic target.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.